Market Overview
On Thursday, the 22nd of October 2026, Urogen Pharma (ticker URGN) posted a modest rise of 2.52 % during the 24‑hour trading window that closed at 05:38 AM Central European Time. At the close, one share of Urogen was priced at USD 35.48 on the most active exchanges. The company’s current share supply stands at 48.9 million, and its market capitalization is USD 1.70 billion. In the last 24 hours, roughly USD 26.2 million worth of shares changed hands.
The stock’s performance over the past month, however, has been markedly negative. Since the close of the previous month’s trading day, Urogen shares have fallen 18.96 %. The 200‑day simple moving average sits at USD 30.80, indicating that the current price is well above its recent medium‑term average. The all‑time high for the past 52 weeks was USD 50.81, recorded on 19 August 2026, while the 52‑week low reached USD 16.50 on 30 March 2026.
Comparative Context
Other notable performers in the same 24‑hour window include:
| Ticker | Daily Change | Current Price (USD) | Market Cap (USD) |
|---|---|---|---|
| PRCH | +3.00 % | 18.59 | 2 billion |
| BFLY | –2.14 % | 7.10 | 2 billion |
| OPEN | +0.49 % | 1.95 | 2 billion |
| SONO | +2.60 % | 17.47 | 2 billion |
| XERS | +1.64 % | 10.78 | 2 billion |
Sonos (SONO) also reports a price‑to‑earnings ratio of 36.62, underscoring the valuation dynamics that accompany high‑growth tech and biotech stocks.
Company Background
UroGen Pharma Ltd. is a clinical‑stage biopharmaceutical enterprise headquartered in New York, United States. The firm is dedicated to the discovery and development of novel therapies that aim to redefine the standard of care for a range of urological diseases, with a particular emphasis on uro‑oncology. UroGen’s digital presence can be accessed at www.urogen.com . The company went public on the Nasdaq stock exchange on 4 May 2017 and has since pursued a strategy centered on early‑stage clinical research and strategic partnerships.
